Cargando…
Functional and structural characteristics in patients with diabetic macular oedema after switching from ranibizumab to aflibercept treatment. Three year results in real world settings
BACKGROUND: Our aim was to examine the long term anatomical and functional outcomes in patients with refractory diabetic macular oedema (DMO) undergoing treatment switch from ranibizumab to aflibercept. METHODS: Retrospective review of patients with DMO undergoing treatment switch from ranibizumab t...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8973508/ https://www.ncbi.nlm.nih.gov/pubmed/35365223 http://dx.doi.org/10.1186/s40942-022-00373-5 |
_version_ | 1784680054139125760 |
---|---|
author | Sepetis, Anastasios E. Clarke, Holly Gupta, Bhaskar |
author_facet | Sepetis, Anastasios E. Clarke, Holly Gupta, Bhaskar |
author_sort | Sepetis, Anastasios E. |
collection | PubMed |
description | BACKGROUND: Our aim was to examine the long term anatomical and functional outcomes in patients with refractory diabetic macular oedema (DMO) undergoing treatment switch from ranibizumab to aflibercept. METHODS: Retrospective review of patients with DMO undergoing treatment switch from ranibizumab to aflibercept at a single centre between 2015 and 2017. Primary outcomes were best corrected visual acuity (BCVA) and central macular thickness (CMT). RESULTS: 57 eyes from 44 patients were included. Following switch to aflibercept, median (IQR) BCVA improved to 73 (64–77) letters at 3 months (p = 0.0006), to 73 (61–78) letters at 6 months (p = 0.0042), to 73 (65–77) at 9 months (p = 0.0006), and to 73 (63–75) letters at 18 months (p = 0.0444). At 36 months following switch, 12 eyes had gained > 10 letters, 5 eyes had gained 5–9 letters, 25 remained stable (± 5 letters), 7 eyes lost 5–9 letters and 8 eyes lost > 10 letters. A significant reduction in CMT at all trimesters following treatment switch was found except at month 24. CONCLUSIONS: We provide real world data suggesting a sustained anatomical and functional benefit of switching from ranibizumab to aflibercept in the treatment of refractory DMO. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40942-022-00373-5. |
format | Online Article Text |
id | pubmed-8973508 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-89735082022-04-02 Functional and structural characteristics in patients with diabetic macular oedema after switching from ranibizumab to aflibercept treatment. Three year results in real world settings Sepetis, Anastasios E. Clarke, Holly Gupta, Bhaskar Int J Retina Vitreous Original Article BACKGROUND: Our aim was to examine the long term anatomical and functional outcomes in patients with refractory diabetic macular oedema (DMO) undergoing treatment switch from ranibizumab to aflibercept. METHODS: Retrospective review of patients with DMO undergoing treatment switch from ranibizumab to aflibercept at a single centre between 2015 and 2017. Primary outcomes were best corrected visual acuity (BCVA) and central macular thickness (CMT). RESULTS: 57 eyes from 44 patients were included. Following switch to aflibercept, median (IQR) BCVA improved to 73 (64–77) letters at 3 months (p = 0.0006), to 73 (61–78) letters at 6 months (p = 0.0042), to 73 (65–77) at 9 months (p = 0.0006), and to 73 (63–75) letters at 18 months (p = 0.0444). At 36 months following switch, 12 eyes had gained > 10 letters, 5 eyes had gained 5–9 letters, 25 remained stable (± 5 letters), 7 eyes lost 5–9 letters and 8 eyes lost > 10 letters. A significant reduction in CMT at all trimesters following treatment switch was found except at month 24. CONCLUSIONS: We provide real world data suggesting a sustained anatomical and functional benefit of switching from ranibizumab to aflibercept in the treatment of refractory DMO. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40942-022-00373-5. BioMed Central 2022-04-01 /pmc/articles/PMC8973508/ /pubmed/35365223 http://dx.doi.org/10.1186/s40942-022-00373-5 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Original Article Sepetis, Anastasios E. Clarke, Holly Gupta, Bhaskar Functional and structural characteristics in patients with diabetic macular oedema after switching from ranibizumab to aflibercept treatment. Three year results in real world settings |
title | Functional and structural characteristics in patients with diabetic macular oedema after switching from ranibizumab to aflibercept treatment. Three year results in real world settings |
title_full | Functional and structural characteristics in patients with diabetic macular oedema after switching from ranibizumab to aflibercept treatment. Three year results in real world settings |
title_fullStr | Functional and structural characteristics in patients with diabetic macular oedema after switching from ranibizumab to aflibercept treatment. Three year results in real world settings |
title_full_unstemmed | Functional and structural characteristics in patients with diabetic macular oedema after switching from ranibizumab to aflibercept treatment. Three year results in real world settings |
title_short | Functional and structural characteristics in patients with diabetic macular oedema after switching from ranibizumab to aflibercept treatment. Three year results in real world settings |
title_sort | functional and structural characteristics in patients with diabetic macular oedema after switching from ranibizumab to aflibercept treatment. three year results in real world settings |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8973508/ https://www.ncbi.nlm.nih.gov/pubmed/35365223 http://dx.doi.org/10.1186/s40942-022-00373-5 |
work_keys_str_mv | AT sepetisanastasiose functionalandstructuralcharacteristicsinpatientswithdiabeticmacularoedemaafterswitchingfromranibizumabtoaflibercepttreatmentthreeyearresultsinrealworldsettings AT clarkeholly functionalandstructuralcharacteristicsinpatientswithdiabeticmacularoedemaafterswitchingfromranibizumabtoaflibercepttreatmentthreeyearresultsinrealworldsettings AT guptabhaskar functionalandstructuralcharacteristicsinpatientswithdiabeticmacularoedemaafterswitchingfromranibizumabtoaflibercepttreatmentthreeyearresultsinrealworldsettings |